Editorial

John G. Gribben; António Parreira

doi:10.4081/hmr.v1i4.622

Articles

16 June 2009

Vol. 1 No. 4: Maintaining Life: Optimal Strategies to Improve Survival

https://doi.org/10.4081/hmr.v1i4.622

Editorial

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

176

Views

104

Downloads

Authors

John G. Gribben

support@pagepress.org

António Parreira

The advent of rituximab has dramatically changed the management of non-Hodgkin’s lymphoma (NHL), with a corresponding improvement in patient outcomes. After many years in which treatment strategies in NHL remained fairly static, rituximab has been associated with prolonged survival in follicular lymphoma (FL) and an increased cure rate in diffuse large B-cell lymphoma (DLBCL). Initial trials in chronic lymphocytic leukaemia (CLL) also show considerable promise. An opportunity to reflect on these advances, examine recently available clinical data and share experience of clinical practice was provided by the ‘Maintaining Life: Optimal Strategies to Improve Survival – Expert Investigator Forum 2007’.